Document:

REGISTRATION RIGHTS
AGREEMENT

 

REGISTRATION RIGHTS
AGREEMENT (this "Agreement"), dated as of February 18, 2013, by and between CYTOMEDIX, INC., a Delaware
corporation, (the "Company"), and LINCOLN PARK CAPITAL FUND, LLC, an
Illinois limited liability company (together with it permitted assigns, the “Buyer”). Capitalized terms
used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between
the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the
"Purchase Agreement").

 

WHEREAS:

 

The Company has agreed,
upon the terms and subject to the conditions of the Purchase Agreement, to sell to the Buyer up to Fifteen Million Dollars ($15,000,000)
of the Company’s Common Stock, and to induce the Buyer to enter into the Purchase Agreement, the Company has agreed to provide
certain registration rights under the Securities Act of 1933, as amended, and the rules and regulations thereunder, or any similar
successor statute (collectively, the "Securities Act"), and applicable state securities laws.

 

NOW, THEREFORE,
in consideration of the promises and the mutual covenants contained herein and other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the Company and the Buyer hereby agree as follows:

 

1.           DEFINITIONS.

 

As used in this Agreement,
the following terms shall have the following meanings:

 

a.           "Investor"
means the Buyer, any transferee or assignee thereof to whom a Buyer assigns its rights under this Agreement in accordance with
Section 9 and who agrees to become bound by the provisions of this Agreement and any transferee or assignee thereof to whom a transferee
or assignee assigns its rights under this Agreement in accordance with Section 9 and who agrees to become bound by the provisions
of this Agreement.

 

b.           "Person"
means any individual or entity including but not limited to any corporation, a limited liability company, an association, a partnership,
an organization, a business, an individual, a governmental or political subdivision thereof or a governmental agency.

 

c.           "Register,"
"registered," and "registration" refer to a registration effected by preparing and filing one
or more registration statements of the Company in compliance with the Securities Act and pursuant to Rule 415 under the Securities
Act or any successor rule providing for offering securities on a continuous basis ("Rule 415"), and the declaration
or ordering of effectiveness of such registration statement(s) by the United States Securities and Exchange Commission (the "SEC").

d.           "Registrable
Securities" means (i) all of the Purchase Shares and all of the Commitment Shares which may from time to time be issued
or issuable to the Investor under the Purchase Agreement (without regard to any limitation or restriction on purchases), and (ii)
any shares of capital stock issued or issuable with respect to the Purchase Shares, the Commitment Shares or the Purchase
Agreement as a result of any stock split, stock dividend, recapitalization, exchange or similar event or otherwise, without regard
to any limitation on purchases under the Purchase Agreement.

 

    	 

    	 

    

 

e.           "Registration
Statement" means one or more registration statements of the Company covering only the sale of the Registrable Securities.

 

2.           REGISTRATION.

 

a.           Mandatory
Registration. The Company shall, within seventy five (75) days from the date hereof, file with the SEC an initial Registration
Statement on Form S-1. The initial Registration Statement shall register the maximum number of Registrable Securities that may
be issuable to the Investor pursuant to the Purchase Agreement, subject to Section 2(d) below, and no other securities of the Company.
The Registration Statement, upon filing with the SEC and at the time it is declared effective by the SEC, shall satisfy all of
the requirements of the Securities Act to register the resale of the Registrable Securities by the Investor in accordance with
this Agreement under Rule 415 promulgated under the Securities Act at then-prevailing market prices, and not fixed prices. The
Investor and its counsel shall have a reasonable opportunity to review and comment upon such Registration Statement or amendment
to such Registration Statement and any related prospectus prior to its filing with the SEC. Investor shall furnish all information
reasonably requested by the Company for inclusion therein. The Company shall use its commercially reasonable efforts to have the
Registration Statement or amendment declared effective by the SEC at the earliest possible date after the filing thereof. The Company
shall use its commercially reasonable efforts to keep the Registration Statement effective pursuant to Rule 415 promulgated under
the Securities Act and available for sales of all of the Registrable Securities covered thereby at all times until the earlier
of (i) the date as of which the Investor may sell any previously unsold Registrable Securities covered thereby without restriction
pursuant to Rule 144 promulgated under the Securities Act (or successor thereto) or (ii) the date on which the Investor shall have
sold all the Registrable Securities covered thereby and no Available Amount remains under the Purchase Agreement (the "Registration
Period"). The Registration Statement (including any amendments or supplements thereto and prospectuses contained therein)
shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein, or necessary
to make the statements therein, in light of the circumstances in which they were made, not misleading.

 

b.           Rule
424 Prospectus. The Company shall, as required by applicable securities regulations, from time to time file with the SEC, pursuant
to Rule 424 promulgated under the Securities Act, the prospectus and prospectus supplements, if any, to be used in connection with
sales of the Registrable Securities under the Registration Statement. The Investor and its counsel shall have a reasonable opportunity
to review and comment upon such prospectus prior to its filing with the SEC. The Investor shall use its reasonable best efforts
to comment upon such prospectus within one (1) Business Day from the date the Investor receives the final version of such prospectus.

 

c.           Sufficient
Number of Shares Registered. In the event the number of shares available under the initial Registration Statement is insufficient
to cover all of the Registrable Securities, the Company shall amend the initial Registration Statement or file a new Registration
Statement (a “New Registration Statement”), so as to cover all of the Registrable Securities not covered by
such initial Registration Statement as soon as practicable, but in any event not later than ten (10) Business Days after the necessity
therefor arises, subject to any limits that may be imposed by the SEC pursuant to Rule 415 under the Securities Act. The Company
shall use its commercially reasonable efforts to cause such amendment and/or New Registration Statement to become effective as
soon as practicable following the filing thereof.

 

    	2

    	 

    

 

d.          Offering. If
the staff of the SEC (the “Staff”) or the SEC seeks to characterize any offering pursuant to a Registration
Statement filed pursuant to this Agreement as constituting an offering of securities that does not permit such Registration Statement
to become effective and be used for resales by the Investor under Rule 415 at then-prevailing market prices (and not fixed prices)
(or as otherwise may be acceptable to the Investor), or if after the filing of the initial Registration Statement with the SEC
pursuant to Section 2(a), the Company is otherwise required by the Staff or the SEC to reduce the number of Registrable Securities
included in such initial Registration Statement, then the Company shall reduce the number of Registrable Securities to be included
in such initial Registration Statement (with the prior consent, which shall not be unreasonably withheld, of the Investor and its
legal counsel as to the specific Registrable Securities to be removed therefrom) until such time as the Staff and the SEC shall
so permit such Registration Statement to become effective and be used as aforesaid. In the event of any reduction in Registrable
Securities pursuant to this paragraph, the Company shall file one or more New Registration Statements in accordance with Section
2(c) until such time as all Registrable Securities have been included in Registration Statements that have been declared effective
and the prospectus contained therein is available for use by the Investor. Notwithstanding any provision herein or in the Purchase
Agreement to the contrary, the Company’s obligations to register Registrable Securities (and any related conditions to the
Investor’s obligations) shall be qualified as necessary to comport with any requirement of the SEC or the Staff as addressed
in this Section 2(d).

 

3.           RELATED
OBLIGATIONS.

 

With respect to the
Registration Statement and whenever any Registrable Securities are to be registered pursuant to Section 2 including on any New
Registration Statement, the Company shall use its commercially reasonable efforts to effect the registration of the Registrable
Securities in accordance with this Agreement and, pursuant thereto, the Company shall have the following obligations:

 

a.           The
Company shall prepare and file with the SEC such amendments (including post-effective amendments) and supplements to any registration
statement and the prospectus used in connection with such registration statement, which prospectus is to be filed pursuant to Rule
424 promulgated under the Securities Act, as may be necessary to keep the Registration Statement or any New Registration Statement
effective at all times during the Registration Period, and, during such period, comply with the provisions of the Securities Act
with respect to the disposition of all Registrable Securities of the Company covered by the Registration Statement or any New Registration
Statement until such time as all of such Registrable Securities shall have been disposed of in accordance with this Agreement by
the Buyer as set forth in such registration statement.

 

b.           The
Company shall permit the Investor to review and comment upon the Registration Statement or any New Registration Statement and all
amendments and supplements thereto at least two (2) Business Days prior to their filing with the SEC, and not file any document
in a form to which Investor reasonably objects. The Investor shall use its reasonable best efforts to comment upon the Registration
Statement or any New Registration Statement and any amendments or supplements thereto within two (2) Business Days from the date
the Investor receives the final version thereof. The Company shall furnish to the Investor, without charge any correspondence from
the SEC or the staff of the SEC to the Company or its representatives relating to the Registration Statement or any New Registration
Statement.

 

c.           Upon
request of the Investor, the Company shall furnish to the Investor, (i) promptly after the same is prepared and filed with the
SEC, at least one copy of such registration statement and any amendment(s) thereto, including financial statements and schedules,
all documents incorporated therein by reference and all exhibits, (ii) upon the effectiveness of any registration statement, a
copy of the prospectus included in such registration statement and all amendments and supplements thereto (or such other number
of copies as the Investor may reasonably request) and (iii) such other documents, including copies of any preliminary or final
prospectus, as the Investor may reasonably request from time to time in order to facilitate the disposition of the Registrable
Securities owned by the Investor.

 

    	3

    	 

    

 

d.           The
Company shall use commercially reasonable efforts to (i) register and qualify the Registrable Securities covered by a registration
statement under such other securities or "blue sky" laws of such jurisdictions in the United States as the Investor reasonably
requests, (ii) prepare and file in those jurisdictions, such amendments (including post-effective amendments) and supplements to
such registrations and qualifications as may be necessary to maintain the effectiveness thereof during the Registration Period,
(iii) take such other actions as may be necessary to maintain such registrations and qualifications in effect at all times during
the Registration Period, and (iv) take all other actions reasonably necessary or advisable to qualify the Registrable Securities
for sale in such jurisdictions; provided, however, that the Company shall not be required in connection therewith or as a condition
thereto to (x) qualify to do business in any jurisdiction where it would not otherwise be required to qualify but for this Section
3(d), (y) subject itself to general taxation in any such jurisdiction, or (z) file a general consent to service of process in any
such jurisdiction. The Company shall promptly notify the Investor who holds Registrable Securities of the receipt by the Company
of any notification with respect to the suspension of the registration or qualification of any of the Registrable Securities for
sale under the securities or "blue sky" laws of any jurisdiction in the United States or its receipt of actual notice
of the initiation or threatening of any proceeding for such purpose.

 

e.           As
promptly as practicable after becoming aware of such event or facts, the Company shall notify the Investor in writing of the happening
of any event or existence of such facts as a result of which the prospectus included in any registration statement, as then in
effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary
to make the statements therein, in light of the circumstances under which they were made, not misleading, and promptly prepare
a supplement or amendment to such registration statement to correct such untrue statement or omission, and deliver a copy of such
supplement or amendment to the Investor (or such other number of copies as the Investor may reasonably request). The Company shall
also promptly notify the Investor in writing (i) when a prospectus or any prospectus supplement or post-effective amendment has
been filed, and when a registration statement or any post-effective amendment has become effective (notification of such effectiveness
shall be delivered to the Investor by facsimile on the same day of such effectiveness and by overnight mail), (ii) of any request
by the SEC for amendments or supplements to any registration statement or related prospectus or related information, and (iii)
of the Company's reasonable determination that a post-effective amendment to a registration statement would be appropriate.

 

f.            The
Company shall use its commercially reasonable efforts to prevent the issuance of any stop order or other suspension of effectiveness
of any registration statement, or the suspension of the qualification of any Registrable Securities for sale in any jurisdiction
and, if such an order or suspension is issued, to obtain the withdrawal of such order or suspension at the earliest possible moment
and to notify the Investor of the issuance of such order and the resolution thereof or its receipt of actual notice of the initiation
or threat of any proceeding for such purpose.

 

g.           The
Company shall (i) cause all the Registrable Securities to be listed on each securities exchange on which securities of the same
class or series issued by the Company are then listed, and (ii) secure designation and quotation of all the Registrable Securities
on the Principal Market. The Company shall pay all fees and expenses in connection with satisfying its obligation under this Section.

 

h.           The
Company shall cooperate with the Investor to facilitate the timely issuance of the Registrable Securities as set forth in the Purchase
Agreement, it being agreed that all Registrable Securities to be issued pursuant to the Purchase Agreement shall be issued as DWAC
Shares.

 

    	4

    	 

    

 

i.            The
Company shall at all times provide a transfer agent and registrar with respect to its Common Stock.

 

j.            If
reasonably requested by the Investor, the Company shall (i) immediately incorporate in a prospectus supplement or post-effective
amendment such information as the Investor believes should be included therein relating to the sale and distribution of Registrable
Securities, including, without limitation, information with respect to the number of Registrable Securities being sold, the purchase
price being paid therefor and any other terms of the offering of the Registrable Securities; (ii) make all required filings of
such prospectus supplement or post-effective amendment as soon as notified of the matters to be incorporated in such prospectus
supplement or post-effective amendment; and (iii) supplement or make amendments to any registration statement.

 

k.          The
Company shall use its commercially reasonable efforts to cause the Registrable Securities covered by any registration statement
to be registered with or approved by such other governmental agencies or authorities as may be necessary to consummate the disposition
of such Registrable Securities.

 

l.            Within
one (1) Business Day after any registration statement which includes the Registrable Securities is ordered effective by the SEC,
the Company shall deliver, and shall cause legal counsel for the Company to deliver, to the transfer agent for such Registrable
Securities (with copies to the Investor) confirmation that such registration statement has been declared effective by the SEC
in the form attached hereto as Exhibit A. Thereafter, if requested by the Buyer at any time, the Company shall require
its counsel to deliver to the Buyer a written confirmation whether or not the effectiveness of such registration statement has
lapsed at any time for any reason (including, without limitation, the issuance of a stop order) and whether or not the registration
statement is current and available to the Buyer for sale of all of the Registrable Securities.

 

m.           The
Company shall take all other reasonable actions necessary to expedite and facilitate disposition by the Investor of Registrable
Securities pursuant to any registration statement.

 

4.           OBLIGATIONS
OF THE INVESTOR.

 

a.           The
Company shall notify the Investor in writing of the information the Company reasonably requires from the Investor in connection
with any registration statement hereunder. Within two (2) business days of the Company’s request, the Investor shall furnish
to the Company such information regarding itself, the Registrable Securities held by it and the intended method of disposition
of the Registrable Securities held by it as shall be reasonably required to effect the registration of such Registrable Securities
and shall execute such documents in connection with such registration as the Company may reasonably request.

 

b.           The
Investor agrees to cooperate with the Company as reasonably requested by the Company in connection with the preparation and filing
of any registration statement hereunder.

 

c.           The
Investor agrees that, upon receipt of any notice from the Company of the happening of any event or existence of facts of the kind
described in Section 3(f) or the first sentence of 3(e), the Investor will immediately discontinue disposition of Registrable Securities
pursuant to any registration statement(s) covering such Registrable Securities until the Investor's receipt of the copies of the
supplemented or amended prospectus contemplated by Section 3(f) or the first sentence of 3(e). Notwithstanding anything to the
contrary, the Company shall cause its transfer agent to promptly deliver shares of Common Stock without any restrictive legend
in accordance with the terms of the Purchase Agreement in connection with any sale of Registrable Securities with respect to which
an Investor has entered into a contract for sale prior to the Investor's receipt of a notice from the Company of the happening
of any event of the kind described in Section 3(f) or the first sentence of 3(e) and for which the Investor has not yet settled.

 

    	5

    	 

    

 

 

5.           EXPENSES
OF REGISTRATION.

 

All reasonable expenses,
other than sales or brokerage commissions, incurred in connection with registrations, filings or qualifications pursuant to Sections
2 and 3, including, without limitation, all registration, listing and qualifications fees, printers and accounting fees, and fees
and disbursements of counsel for the Company, shall be paid by the Company.

 

6.           INDEMNIFICATION.

 

a.           To
the fullest extent permitted by law, the Company will, and hereby does, indemnify, hold harmless and defend the Investor, each
Person, if any, who controls the Investor, the members, the directors, officers, partners, employees, agents, representatives of
the Investor and each Person, if any, who controls the Investor within the meaning of the Securities Act or the Securities Exchange
Act of 1934, as amended (the "Exchange Act") (each, an "Indemnified Person"), against any losses,
claims, damages, liabilities, judgments, fines, penalties, charges, costs, attorneys' fees, amounts paid in settlement or expenses,
joint or several, (collectively, "Claims") incurred in investigating, preparing or defending any action, claim,
suit, inquiry, proceeding, investigation or appeal taken from the foregoing by or before any court or governmental, administrative
or other regulatory agency, body or the SEC, whether pending or threatened, whether or not an indemnified party is or may be a
party thereto ("Indemnified Damages"), to which any of them may become subject insofar as such Claims (or actions
or proceedings, whether commenced or threatened, in respect thereof) arise out of or are based upon: (i) any untrue statement or
alleged untrue statement of a material fact in the Registration Statement, any New Registration Statement or any post-effective
amendment thereto or in any filing made in connection with the qualification of the offering under the securities or other "blue
sky" laws of any jurisdiction in which Registrable Securities are offered ("Blue Sky Filing"), or the omission
or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading,
(ii) any untrue statement or alleged untrue statement of a material fact contained in the final prospectus (as amended or supplemented,
if the Company files any amendment thereof or supplement thereto with the SEC) or the omission or alleged omission to state therein
any material fact necessary to make the statements made therein, in light of the circumstances under which the statements therein
were made, not misleading, (iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any
other law, including, without limitation, any state securities law, or any rule or regulation thereunder relating to the offer
or sale of the Registrable Securities pursuant to the Registration Statement or any New Registration Statement or (iv) any material
violation by the Company of this Agreement (the matters in the foregoing clauses (i) through (iv) being, collectively, "Violations").
The Company shall reimburse each Indemnified Person promptly as such expenses are incurred and are due and payable, for any reasonable
legal fees or other reasonable expenses incurred by them in connection with investigating or defending any such Claim. Notwithstanding
anything to the contrary contained herein, the indemnification agreement contained in this Section 6(a): (i) shall not apply to
a Claim by an Indemnified Person arising out of or based upon a Violation which occurs in reliance upon and in conformity with
information about the Investor furnished in writing to the Company by any Indemnified Person expressly for use in connection with
the preparation of the Registration Statement, any New Registration Statement or any such amendment thereof or supplement thereto,
if such prospectus was timely made available by the Company pursuant to Section 3(c) or Section 3(e); (ii) with respect to any
superseded prospectus, shall not inure to the benefit of any such person from whom the person asserting any such Claim purchased
the Registrable Securities that are the subject thereof (or to the benefit of any person controlling such person) if the untrue
statement or omission of material fact contained in the superseded prospectus was corrected in the revised prospectus, as then
amended or supplemented, if such revised prospectus was timely made available by the Company pursuant to Section 3(c) or Section
3(e), and the Investor was promptly advised in writing not to use the incorrect prospectus prior to the use giving rise to a violation
and such Indemnified Person, notwithstanding such advice, used it; (iii) shall not be available to the extent such Claim is based
on a failure of the Investor to deliver or to cause to be delivered the prospectus made available by the Company, if such prospectus
was timely made available by the Company pursuant to Section 3(c) or Section 3(e); and (iv) shall not apply to amounts paid in
settlement of any Claim if such settlement is effected without the prior written consent of the Company, which consent shall not
be unreasonably withheld. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf
of the Indemnified Person and shall survive the transfer of the Registrable Securities by the Investor pursuant to Section 9.

 

    	6

    	 

    

 

 

b.           In
connection with the Registration Statement or any New Registration Statement, the Investor agrees to severally and not jointly
indemnify, hold harmless and defend, to the same extent and in the same manner as is set forth in Section 6(a), the Company, each
of its directors, each of its officers who signs the Registration Statement or any New Registration Statement, each Person, if
any, who controls the Company within the meaning of the Securities Act or the Exchange Act (collectively and together with an Indemnified
Person, an "Indemnified Party"), against any Claim or Indemnified Damages to which any of them may become subject,
under the Securities Act, the Exchange Act or otherwise, insofar as such Claim or Indemnified Damages arise out of or are based
upon any Violation, in each case to the extent, and only to the extent, that such Violation occurs in reliance upon and in conformity
with written information about the Investor set forth on Exhibit B attached hereto and furnished to the Company by the Investor
expressly for use in connection with such registration statement; and, subject to Section 6(d), the Investor will reimburse any
legal or other expenses reasonably incurred by them in connection with investigating or defending any such Claim; provided, however,
that the indemnity agreement contained in this Section 6(b) and the agreement with respect to contribution contained in Section
7 shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent of
the Investor, which consent shall not be unreasonably withheld; provided, further, however, that the Investor shall be liable under
this Section 6(b) for only that amount of a Claim or Indemnified Damages as does not exceed the net proceeds to the Investor as
a result of the sale of Registrable Securities pursuant to such registration statement. Such indemnity shall remain in full force
and effect regardless of any investigation made by or on behalf of such Indemnified Party and shall survive the transfer of the
Registrable Securities by the Investor pursuant to Section 9.

 

c.           Promptly
after receipt by an Indemnified Person or Indemnified Party under this Section 6 of notice of the commencement of any action or
proceeding (including any governmental action or proceeding) involving a Claim, such Indemnified Person or Indemnified Party shall,
if a Claim in respect thereof is to be made against any indemnifying party under this Section 6, deliver to the indemnifying party
a written notice of the commencement thereof, and the indemnifying party shall have the right to participate in, and, to the extent
the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume control of the defense
thereof with counsel mutually satisfactory to the indemnifying party and the Indemnified Person or the Indemnified Party, as the
case may be; provided, however, that an Indemnified Person or Indemnified Party shall have the right to retain its own counsel
with the fees and expenses to be paid by the indemnifying party, if, in the reasonable opinion of counsel retained by the indemnifying
party, the representation by such counsel of the Indemnified Person or Indemnified Party and the indemnifying party would be inappropriate
due to actual or potential differing interests between such Indemnified Person or Indemnified Party and any other party represented
by such counsel in such proceeding. The Indemnified Party or Indemnified Person shall cooperate fully with the indemnifying party
in connection with any negotiation or defense of any such action or claim by the indemnifying party and shall furnish to the indemnifying
party all information reasonably available to the Indemnified Party or Indemnified Person which relates to such action or claim.
The indemnifying party shall keep the Indemnified Party or Indemnified Person fully apprised at all times as to the status of the
defense or any settlement negotiations with respect thereto. No indemnifying party shall be liable for any settlement of any action,
claim or proceeding effected without its written consent, provided, however, that the indemnifying party shall not unreasonably
withhold, delay or condition its consent. No indemnifying party shall, without the consent of the Indemnified Party or Indemnified
Person, consent to entry of any judgment or enter into any settlement or other compromise which does not include as an unconditional
term thereof the giving by the claimant or plaintiff to such Indemnified Party or Indemnified Person of a release from all liability
in respect to such claim or litigation. Following indemnification as provided for hereunder, the indemnifying party shall be subrogated
to all rights of the Indemnified Party or Indemnified Person with respect to all third parties, firms or corporations relating
to the matter for which indemnification has been made. The failure to deliver written notice to the indemnifying party within a
reasonable time of the commencement of any such action shall not relieve such indemnifying party of any liability to the Indemnified
Person or Indemnified Party under this Section 6, except to the extent that the indemnifying party is prejudiced in its ability
to defend such action.

 

    	7

    	 

    

 

d.           The
indemnification required by this Section 6 shall be made by periodic payments of the amount thereof during the course of the investigation
or defense, as and when bills are received or Indemnified Damages are incurred.

 

e.           The
indemnity agreements contained herein shall be in addition to (i) any cause of action or similar right of the Indemnified Party
or Indemnified Person against the indemnifying party or others, and (ii) any liabilities the indemnifying party may be subject
to pursuant to the law.

 

7.           CONTRIBUTION.

 

To the extent any indemnification
by an indemnifying party is prohibited or limited by law, the indemnifying party agrees to make the maximum contribution with respect
to any amounts for which it would otherwise be liable under Section 6 to the fullest extent permitted by law; provided, however,
that: (i) no seller of Registrable Securities guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the
Securities Act) shall be entitled to contribution from any seller of Registrable Securities who was not guilty of fraudulent misrepresentation;
and (ii) contribution by any seller of Registrable Securities shall be limited in amount to the net amount of proceeds received
by such seller from the sale of such Registrable Securities.

 

8.           REPORTS
AND DISCLOSURE UNDER THE SECURITIES ACTS.

 

With a view to making
available to the Investor the benefits of Rule 144 promulgated under the Securities Act or any other similar rule or regulation
of the SEC that may at any time permit the Investor to sell securities of the Company to the public without registration ("Rule
144"), the Company agrees, at the Company’s sole expense, to:

 

a.           make
and keep public information available, as those terms are understood and defined in Rule 144;

 

b.           file
with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange
Act so long as the Company remains subject to such requirements and the filing of such reports and other documents is required
for the applicable provisions of Rule 144;

 

    	8

    	 

    

 

c.           furnish
to the Investor so long as the Investor owns Registrable Securities, promptly upon request, (i) a written statement by the Company
that it has complied with the reporting and or disclosure provisions of Rule 144, the Securities Act and the Exchange Act, (ii)
a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company,
and (iii) such other information as may be reasonably requested to permit the Investor to sell such securities pursuant to Rule
144 without registration; and

 

d.           take
such additional action as is requested by the Investor to enable the Investor to sell the Registrable Securities pursuant to Rule
144, including, without limitation, delivering all such legal opinions, consents, certificates, resolutions and instructions to
the Company’s Transfer Agent as may be requested from time to time by the Investor and otherwise fully cooperate with Investor
and Investor’s broker to effect such sale of securities pursuant to Rule 144.

 

The Company agrees
that damages may be an inadequate remedy for any breach of the terms and provisions of this Section 8 and that Investor shall,
whether or not it is pursuing any remedies at law, be entitled to equitable relief in the form of a preliminary or permanent injunctions,
without having to post any bond or other security, upon any breach or threatened breach of any such terms or provisions.

 

9.           ASSIGNMENT
OF REGISTRATION RIGHTS.

 

The Company shall not
assign this Agreement or any rights or obligations hereunder without the prior written consent of the Investor. The Investor may
not assign its rights under this Agreement without the written consent of the Company, other than to an affiliate of the Investor
controlled by Jonathan Cope or Josh Scheinfeld.

 

10.         AMENDMENT
OF REGISTRATION RIGHTS.

 

Provisions of this Agreement
may be amended and the observance thereof may be waived (either generally or in a particular instance and either retroactively
or prospectively), only with the written consent of the Company and the Investor.

 

11.         MISCELLANEOUS.

 

a.           A
Person is deemed to be a holder of Registrable Securities whenever such Person owns or is deemed to own of record such Registrable
Securities. If the Company receives conflicting instructions, notices or elections from two or more Persons with respect to the
same Registrable Securities, the Company shall act upon the basis of instructions, notice or election received from the registered
owner of such Registrable Securities.

 

b.           Any
notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must be
in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent
by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending
party); or (iii) one (1) Business Day after deposit with a nationally recognized overnight delivery service, in each case properly
addressed to the party to receive the same. The addresses and facsimile numbers for such communications shall be:

 

    	9

    	 

    

 

If to the Company:

Cytomedix,
Inc.

209 Perry Parkway, Suite 7

Gaithersburg, MD 20877

Telephone:        240-499-2680

Facsimile:         240-499-2690

Attention:         CEO

 

With a copy to:

Cozen O’Connor

1627 I Street,
NW, Suite 1100

Washington, DC
20006

Telephone:         202-912-4800

Attention:          Alec
Orudjev, Esq.

 

If to the Investor:

Lincoln Park Capital
Fund, LLC

440 N. Wells, Suite 410

Chicago, IL 60654

Telephone:        312-822-9300

Facsimile:          312-822-9301

Attention:          Josh Scheinfeld/Jonathan
Cope

 

With copies to:

Greenberg Traurig, LLP

The MetLife Building

200 Park Avenue

New York, NY 10166

Telephone:        (212) 801-9200

Facsimile:         (212) 801-6400

E-mail:              marsicoa@gtlaw.com

Attention:          Anthony J. Marsico,
Esq.

 

or at such other address and/or facsimile
number and/or to the attention of such other person as the recipient party has specified by written notice given to each other
party three (3) Business Days prior to the effectiveness of such change. Written confirmation of receipt (A) given by the recipient
of such notice, consent, waiver or other communication, (B) mechanically or electronically generated by the sender's facsimile
machine containing the time, date, recipient facsimile number and an image of the first page of such transmission or (C) provided
by a nationally recognized overnight delivery service, shall be rebuttable evidence of personal service, receipt by facsimile or
receipt from a nationally recognized overnight delivery service in accordance with clause (i), (ii) or (iii) above, respectively.

 

c.           No
provision of this Agreement may be amended or waived by the parties from and after the date that is one Business Day immediately
preceding the initial filing of the Registration Statement with the SEC. Subject to the immediately preceding sentence, no provision
of this Agreement may be (i) amended other than by a written instrument signed by both parties hereto or (ii) waived other than
in a written instrument signed by the party against whom enforcement of such waiver is sought. Failure of any party to exercise
any right or remedy under this Agreement or otherwise, or delay by a party in exercising such right or remedy, shall not operate
as a waiver thereof.

 

    	10

    	 

    

 

d.           The
corporate laws of the State of Delaware shall govern all issues concerning the relative rights of the Company and its stockholders.
All other questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by
the internal laws of the State of Illinois, without giving effect to any choice of law or conflict of law provision or rule (whether
of the State of Illinois or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than
the State of Illinois. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting
the City of Chicago, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated
hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim
that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an
inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal
service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such
party at the address for such notices to it under this Agreement and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any manner permitted by law. If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such
invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction
or the validity or enforceability of any provision of this Agreement in any other jurisdiction. EACH PARTY HEREBY IRREVOCABLY
WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION
HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

e.           This
Agreement, and the Purchase Agreement constitute the entire agreement among the parties hereto with respect to the subject matter
hereof and thereof. There are no restrictions, promises, warranties or undertakings, other than those set forth or referred to
herein and therein. This Agreement and the Purchase Agreement supersede all prior agreements and understandings among the parties
hereto with respect to the subject matter hereof and thereof.

 

f.            Subject
to the requirements of Section 9, this Agreement shall inure to the benefit of and be binding upon the successors and permitted
assigns of each of the parties hereto.

 

g.           The
headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof.

 

h.           This
Agreement may be executed in identical counterparts, each of which shall be deemed an original but all of which shall constitute
one and the same agreement. This Agreement, once executed by a party, may be delivered to the other party hereto by facsimile transmission
of a copy of this Agreement bearing the signature of the party so delivering this Agreement.

 

i.            Each
party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver
all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry
out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

 

j.            The
language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent and no rules
of strict construction will be applied against any party.

 

    	11

    	 

    

 

k.          This
Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns, and is not for
the benefit of, nor may any provision hereof be enforced by, any other Person.

 

* * * * * *

 

    	12

    	 

    

 

IN WITNESS WHEREOF,
the parties have caused this Registration Rights Agreement to be duly executed as of day and year first above written.

 

	 	THE COMPANY:
	 	 
	 	CYTOMEDIX, INC.
	 	 
	 	By:	/s/ Martin P. Rosendale
	 	Name:	Martin P. Rosendale
	 	Title:	Chief Executive Officer
	 	 
	 	INVESTOR:
	 	 
	 	LINCOLN PARK CAPITAL FUND, LLC
	 	BY: 	LINCOLN PARK CAPITAL, LLC
	 	BY:	ALEX NOAH INVESTORS, INC. 
	 	 	 
	 	By: 	/s/ Jonathan Cope
	 	Name: 	Jonathan Cope
	 	Title: 	President

 

    	13SECURITIES PURCHASE AGREEMENT

 

This SECURITIES
PURCHASE AGREEMENT (the “Agreement”), dated as of February 19, 2013, by and among Cytomedix, Inc., a Delaware
corporation, with headquarters located at 209 Perry Parkway, Suite 7 Gaithersburg, MD 20877 (the “Company”),
and the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively,
the “Buyers”). Capitalized terms used and not otherwise defined herein shall have the meanings set forth in
that certain Placement Agent Agreement (the “PAA”), dated February 19, 2013, by and between the Company and Burrill,
LLC (the “Placement Agent”).

 

WHEREAS:

 

A.           The
offering and sale of the Securities (as defined below) are being made pursuant to (i) a currently effective shelf registration
statement on Form S-3, which has at least $35,000,000 in unallocated securities registered thereunder, including the “base”
prospectus contained therein (Registration Number 333-183704) (the “Registration Statement”), which Registration
Statement has been declared effective in accordance with the Securities Act of 1933, as amended (the “1933 Act”),
by the United States Securities and Exchange Commission (the “SEC”), (ii) if applicable, certain “free
writing prospectuses” (as the term is defined under Rule 405 of the 1933 Act that have been or will be filed with the SEC
and delivered to each Buyer on or prior to the date hereof, and (iii) a prospectus supplement pursuant to Rule 424(b) under the
1933 Act (the “Prospectus Supplement” and together with the “base” prospectus, the “Prospectus”)
containing certain supplemental information relating to the Securities and the terms of this offering that will be filed with the
SEC and delivered to each Buyer (or made available to each Buyer by the filing by the Company of an electronic version thereof
with the SEC), along with the Company’s counterpart to this Agreement.

 

B.           Each
Buyer wishes to purchase, and the Company wishes to sell, upon the terms and conditions stated in this Agreement, (i) a certain
number of shares (the “Shares”) of common stock, par value $.0001 per share, of the Company (the “Common
Stock”) and (ii) five-year warrants (the “Warrant,” collectively, the “Warrants”)
to purchase a certain number of shares of Common Stock in substantially the form attached hereto as Exhibit A, for the Purchase
Price (as defined below) set forth opposite such Buyer’s name in columns (3) and (4) on the Schedule of Buyers (which aggregate
amount for all Buyers together shall be 9,090,900 shares of Common Stock and 6,363,630 Warrants, and shall collectively be
referred to herein as the “Securities”).

 

NOW, THEREFORE, in consideration
of the above premises and the mutual covenants contained below and other good and valuable consideration, the receipt and sufficiency
of which is hereby acknowledged, and intending to be legally bound, the Company and each Buyer hereby agree as follows:

 

    	 

    	 

    

 

1.          PURCHASE
AND SALE OF SECURITIES.

 

(a)          Purchase
of Securities.

 

Subject to the satisfaction
(or waiver) of the conditions set forth in Sections 5 and 6 below, the Company shall issue and sell to each Buyer, and each Buyer
severally, but not jointly, agrees to purchase from the Company on the Closing Date the number of Shares and Warrants as is
set forth opposite such Buyer’s name in columns (3) and (4) on the Schedule of Buyers. The Closing (as defined below) shall
occur on the Closing Date (as defined below).

 

(b)          Purchase
Price. The purchase price for the Securities to be purchased by each Buyer at the Closing shall be $0.55 per unit, consisting
of 1 share of common stock and the equivalent of five-year warrants to purchase 0.70 shares of common stock (the “Purchase
Price”).

 

(c)          Closing
Date. Payment of the purchase price for (however, in the case of investments by the Maryland Venture Fund (Department of Business
and Economic Development of the State of Maryland (hereinafter referred to as the “DBED”), execution and delivery of
this Agreement to the Company), and delivery of, the Securities shall be made at a closing (the “Closing”) at
the offices of SorinRand LLP, counsel for the Placement Agent, located at 515 Fifth Avenue, 13th Floor, New York, New York, at
10:00 a.m., local time, on no later than the third business day (as permitted under Rule 15c6-1 under the Securities Exchange Act
of 1934, as amended (collectively with the rules and regulations promulgated thereunder, the “Exchange Act”)), after
the determination of the public offering price of the Securities and entry by the Company into this Agreement (such date of payment
and delivery being herein called the “Closing Date”).

 

(d)          Form
of Payment. On the Closing Date, (i) each Buyer shall pay its Purchase Price to the Company for the Shares and Warrants to
be issued and sold to such Buyer at the Closing, by wire transfer of immediately available funds in accordance with the Company’s
written wire instructions or by check, as the case may be, made payable to the order of “Cytomedix, Inc.”, and (ii)
unless otherwise instructed by the Buyer, the Company shall cause Broadridge, Inc., the Company’s transfer agent (the “Transfer
Agent”) through the Depository Trust Company (“DTC”) Fast Automated Securities Transfer Program, to
credit such aggregate number of Shares that such Buyer is purchasing as is set forth opposite such Buyer’s name in column
(3) of the Schedule of Buyers to such Buyer’s or its designee’s balance account with DTC through its Deposit Withdrawal
Agent SEC system. The executed Warrant shall be delivered in accordance with the terms thereof.

 

2.          REPRESENTATIONS
AND WARRANTIES OF EACH BUYER.

 

Each Buyer represents and warrants with
respect to only itself that:

 

(a)          The
Buyer is purchasing the Securities for its own account, in the ordinary course of its business and the Buyer has no arrangement
with any individual, corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, foreign or domestic government (or an agency or subdivision thereof) or other entity of any kind
(each, a “Person”) to participate in the distribution of the Securities. The Buyer represents that it has received
the Registration Statement and the Prospectus prior to or in connection with its receipt of this Agreement. In connection with
its decision to purchase the Securities, the Buyer has relied only upon the Prospectus and the documents incorporated by reference
therein, and the representations and warranties of the Company contained herein and has not relied upon any representations by
the representatives of the Company or the Placement Agent.

 

    	2

    	 

    

 

(b)          Other
than consummating the transactions contemplated hereunder, the Buyer has not directly or indirectly, nor has any Person acting
on behalf of or pursuant to any understanding with such Buyer, executed any purchases or sales, including “short sale”
(as such term is defined in Section 242.200 of Regulation SHO of the 1934 Act), of the securities of the Company during the period
commencing as of the time that such Buyer first received a written term sheet from the Company or any other Person representing
the Company setting forth the material terms of the transactions contemplated hereunder and ending immediately prior to the execution
hereof. Notwithstanding the foregoing, in the case of a Buyer that is a multi-managed investment vehicle whereby separate portfolio
managers manage separate portions of such Buyer’s assets and the portfolio managers have no direct knowledge of the investment
decisions made by the portfolio managers managing other portions of such Buyer’s assets, the representation set forth above
shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase
the Securities covered by this Agreement. Other than to other Persons party to this Agreement, such Buyer has maintained the confidentiality
of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding
the foregoing, for avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any
actions, with respect to the identification of the availability of, or securing of, available shares to borrow in order to effect
short sales or similar transactions in the future.

 

(c)          The
Buyer hereby represents and warrants to the Company that it is an institutional accredited investor as that term is defined in
Rule 501(a)(1), (2), (3) or (7) of Regulation D promulgated under the Securities Act (or their functional equivalents) and further
represents and warrants to the Company (and understands that the Company shall rely upon such representations and warranties) that
the Buyer also meets one of the definitions of “institutional buyer”, “financial institution”, “institutional
investor”, “accredited institutional investor” or their functional equivalents under the state Blue sky laws,
rules and regulations of respective jurisdiction of such Buyer’s organization or residence or, as it applies to the DBED,
it is a governmental agency or instrumentality for purposes of §11-602(8) of the Corporations and Associations Article, Annotated
Code of Maryland.

 

(d)          The
Buyer hereby understands and acknowledges that there is no public market for the Warrants being offered by the Company, no such
market is expected to develop, that without an active market, there will be no liquidity for the Warrants. The Buyer hereby
understands and acknowledges that the Warrants may not be transferred to any Person that does not meet the requirements set forth
in Section 2(c) above. The sale and issuance of the securities issuable upon exercise of such Warrants or the payment or receipt
of any part of the consideration for such securities prior to exemption or qualification under the applicable state Blue Sky laws
is unlawful. The rights of all parties to such Warrants are expressly conditioned upon such qualification being obtained, unless
the sale is so exempt. The Buyer further understands and acknowledges that no exercise of such Warrants, in whole or in part, at
any time or times after the Exercise Date and on or before the Termination Date thereof may be made except (a) in compliance with
applicable Blue Sky laws or (b) if the Company has been furnished with both an opinion of counsel for the Warrant holder or any
transferee, which opinion and counsel shall be reasonably satisfactory to the Company, relating to the availability of an exemption
under applicable Blue Sky laws, and assurances that such exercise will be made only in compliance with the conditions of any such
exemption or qualification.

 

    	3

    	 

    

 

(e)          The
Buyer hereby understands and acknowledges that the Warrants being offered by the Company are being acquired for investment purposes
and not with a view to distribution or resale and no transfer, sale, assignment, pledge, hypothecation or other disposition of
such Warrants or any interest therein may be made except (a) in compliance with applicable Blue Sky Laws or (b) if the Company
has been furnished with both an opinion of counsel for the Warrant holder, which opinion and counsel shall be reasonably satisfactory
to the Company, relating to the availability of an exemption under applicable Blue Sky Laws, and assurances that the transfer,
sale, assignment, pledge, hypothecation or other disposition will be made only in compliance with the conditions of any such exemption.

 

(f)          The
Buyer shall not issue any press release or make any other public announcement relating to this Agreement unless the Buyer is advised
by its counsel that such press release or public announcement is required by law. The Buyer will timely make all required filings
and disclosures relating to the Buyer’s purchase of the Securities as may be required under the Securities Exchange Act of
1934, as amended (the “1934 Act”), if any.

 

(g)          The
Buyer has the requisite power and authority to enter into and to consummate the transactions contemplated by this Agreement and
otherwise to carry out its obligations hereunder. The execution and delivery of this Agreement by the Buyer and the consummation
by it of the transactions contemplated hereunder have been duly authorized by all necessary action on the part of the Buyer. This
Agreement has been duly executed by the Buyer and, when delivered in accordance with the terms hereof, will constitute the valid
and binding obligation of the Buyer enforceable against the Buyer in accordance with its terms, except as may be limited by any
bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or other similar laws affecting the enforcement of creditors’
rights generally or by general principles of equity.

 

(h)          The
Buyer understands that nothing in this Agreement or any other materials presented to the Buyer in connection with the purchase
or sale of the Securities constitutes legal, tax or investment advice. The Buyer has consulted such legal, tax or investment advisors
as it, in its sole discretion, deems necessary or appropriate in connection with its purchase of the Securities and has not relied
on the Company or the Placement Agent for any legal, tax or investment advice.

 

(i)          The
Buyer hereby acknowledges that it is acting independently from any other investor in connection with the offering, and that it
is not acting as a member of a “group” (as such term is defined in Rule 13d of the 1934 Act) with any other investor
in connection with the offering.

 

    	4

    	 

    

 

(j)          The
Buyer hereby acknowledges and agrees that the information contained in the Prospectus is confidential and may constitute material
non-public information concerning the Company. The Buyer agrees not to act on or to disclose or communicate such material non-public
information to any other person under circumstances in which it is reasonably foreseeable that such person is likely to purchase
or sell securities of the Company. The Buyer further acknowledges and agrees that it remains responsible for compliance with any
and all U.S. federal and state securities laws, including, without limitation, Regulation FD. The Buyer understands that the Company
will use its best efforts to file a Current Report on Form 8-K no later than the open of business on February 21, 2013 making disclosures
of such information as may be required in compliance with the applicable U.S. federal and state securities laws, rules and regulations.

 

3.          REPRESENTATIONS
AND WARRANTIES OF THE COMPANY.

 

The Company hereby makes the following representations
and warranties to each Buyer:

 

(a)          Organization
and Qualification. The Company is an entity duly organized, validly existing and in good standing under the laws of the State
of Delaware, with the requisite power and authority to own and use its properties and assets and to carry on its business as currently
conducted. The Company is not in violation of any of the provisions of its Certificate of Incorporation, as amended, from time
to time, Bylaws, as amended, from time to time, or other organizational or charter documents (the “Organizational Documents”).
The Company is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction
in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure
to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in (i) an adverse
effect on the legality, validity or enforceability of any Transaction Document (as defined below), (ii) a material and adverse
effect on the results of operations, assets, prospects, business or financial condition of the Company, or (iii) an adverse impairment
to the Company’s ability to perform on a timely basis its obligations under any Transaction Document (any of (i), (ii) or
(iii), a “Material Adverse Effect”).

 

(b)          Authorization;
Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by each of this Agreement and any other documents or agreements executed in connection with the transactions contemplated hereunder
(collectively, the “Transaction Documents”) and otherwise to carry out its obligations hereunder and thereunder
and to issue the Securities in accordance with the terms hereof and thereof. The execution and delivery of each of the Transaction
Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby, including, without limitation,
the issuance of the Securities, have been duly authorized by all necessary action on the part of the Company and no further action
is required by the Company, its Board of Directors or its shareholders in connection herewith and therewith. Each Transaction Document
has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof,
will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except
(a) as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors’
rights generally, (b) as enforceability of any indemnification and contribution provisions may be limited under the federal and
state securities laws and public policy, and (c) that the remedy of specific performance and injunctive and other forms of equitable
relief may be subject to equitable defenses and to the discretion of the court before which any proceeding therefor may be brought.

 

    	5

    	 

    

 

(c)          No
Conflicts. The execution, delivery and performance of the Transaction Documents by the Company and the consummation by the
Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Securities) do
not and will not (i) conflict with or violate any provision of the Organizational Documents, any certificate of designations, preferences
and rights of any outstanding series of preferred stock, or (ii) conflict with, or constitute a default (or an event that with
notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration
or cancellation (with or without notice, lapse of time or both) of, any material agreement, credit facility, note, debt or other
instrument (evidencing a Company debt or otherwise) or other material understanding to which the Company is a party or by which
any property or asset of the Company is bound or affected, or (iii) result in a violation of any law, rule, regulation, order,
judgment, injunction, decree or other restriction of any court or governmental authority to which the Company is subject (including
federal and state securities laws and regulations of the OTB Bulletin Board (the “Principal Market”) that the
Common Stock is listed or quoted for trading on the date in question, or by which any property or asset of the Company is bound
or affected; except in the case of each of clauses (ii) and (iii), such as could not, individually or in the aggregate, have or
reasonably be expected to result in a Material Adverse Effect.

 

(d)          Filings,
Consents and Approvals. Except as may be required under the applicable provisions of the State Blue Sky statutes, the Company
is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration
(collectively, “Consents”) with, any Person in connection with the execution, delivery and performance by the
Company of the Transaction Documents, other than the filing with the SEC of the Prospectus.

 

(e)          Issuance
of the Securities. The issuance of the Shares and the Warrants are duly authorized and, upon issuance in accordance with the
terms of the Transaction Documents, will be validly issued, fully paid and non-assessable and free from all preemptive or similar
rights, taxes, liens, charges and other encumbrances with respect to the issue thereof. As of the Closing, the Company shall have
reserved from its duly authorized capital stock not less than 100% of the maximum number of shares of Common Stock issuable upon
exercise of the Warrants (without taking into account any limitations on the exercise of the Warrants set forth therein). The issuance
of the Warrant Shares is duly authorized, and upon exercise in accordance with the Warrants, the Warrant Shares, when issued, will
be validly issued, fully paid and non-assessable and free from all preemptive or similar rights, taxes, liens, charges and other
encumbrances with respect to the issue thereof, with the holders being entitled to all rights accorded to a holder of Common Stock.
The issuance by the Company of the Securities has been registered under the 1933 Act, the Securities are being issued pursuant
to the Registration Statement. The Registration Statement is effective and available for the issuance of the Securities thereunder
and the Company has not received any notice that the SEC has issued or intends to issue a stop-order with respect to the Registration
Statement or that the SEC otherwise has suspended or withdrawn the effectiveness of the Registration Statement, either temporarily
or permanently, or intends or has threatened in writing to do so. The “Plan of Distribution” section under the Registration
Statement permits the issuance and sale of the Securities hereunder and as contemplated by the other Transaction Documents. Upon
receipt of the Securities, each of the Buyers will have good and marketable title to the Securities. The Registration Statement
and any prospectus included therein, including the Prospectus, complied in all material respects with the requirements of the 1933
Act and the rules and regulations of the SEC promulgated thereunder and all other applicable laws and regulations.

 

    	6

    	 

    

 

(f)          Capitalization.
The capitalization of the Company is as set forth in the Prospectus. Except as set forth in the Prospectus, the Company has not
issued any capital stock since its most recently filed periodic report under the 1934 Act, other than pursuant to the exercise
of employee stock options under the Company’s equity incentive plans, the issuance of shares of Common Stock to employees
pursuant to the Company’s employee stock purchase plans and pursuant to the conversion and/or exercise of any stock or securities
(including stock options of the Company) convertible into or exercisable or exchangeable for Common Stock (“Common Stock
Equivalents”) outstanding as of the date of the most recently filed periodic report under the 1934 Act. No Person has
any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated
by the Transaction Documents. Except as set forth in the Prospectus or (i) as a result of the purchase and sale of the Securities,
(ii) pursuant to the Company’s equity incentive plans and (iii) pursuant to agreements or instruments, filed as
exhibits to SEC Reports incorporated by reference into the Prospectus Supplement, as a result of the purchase and sale of the Securities,
there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating
to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to
subscribe for or acquire, any shares of Common Stock, or contracts, commitments, understandings or arrangements by which the Company
is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents. All of the outstanding shares of
capital stock of the Company are duly authorized and validly issued, fully paid and nonassessable. No further approval or authorization
of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities. Except as set forth
in the Company’s public filings under the Exchange Act, there are no stockholders agreements, voting agreements or other
similar agreements with respect to the Company’s capital stock to which the Company is a party or, to the knowledge of the
Company, between or among any of the Company’s stockholders.

 

(g)          SEC
Reports. The Company has filed all reports required to be filed by it under the 1934 Act, including pursuant to Section 13(a)
or 15(d) thereof, for the twelve months preceding the date hereof (or such shorter period as the Company was required by law to
file such reports) (the foregoing materials being collectively referred to herein as the “SEC Reports”) on a
timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration
of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of
the 1934 Act and the rules and regulations of the SEC promulgated thereunder, and none of the SEC Reports, when filed and/or subsequently
amended or restated, contained any untrue statement of a material fact or omitted to state a material fact required to be stated
therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not
misleading. The Registration Statement and the Prospectus, complied in all material respects with the requirements of the 1933
Act and the rules and regulations of the SEC promulgated thereunder, and none of such Registration Statement or the Prospectus,
contain or contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein
or necessary in order to make the statements therein, in the case of any prospectus in the light of the circumstances under which
they were made, not misleading. The financial statements of the Company included in the SEC Reports comply in all material respects
with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time
of filing or as subsequently amended or restated. Such financial statements have been prepared in accordance with generally accepted
accounting principles applied on a consistent basis during the periods involved (“GAAP”), except as may be otherwise
specified in such financial statements or the notes thereto, and fairly present in all material respects the financial position
of the Company as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject,
in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.

 

    	7

    	 

    

 

(h)          Disclosure.
Except for information relating to the transactions contemplated by the Transaction Documents, set forth in the Prospectus Supplement
with respect to the Securities as required under and in conformity with the 1933 Act, or in the SEC Reports, the Company confirms,
covenants and warrants that neither it nor any Person acting on its behalf, including the Placement Agent, has provided any of
the Buyers or their agents or counsel with any information that the Company believes constitutes material, non-public information.
Furthermore, on the business day following the execution of this Agreement and prior to the commencement of trading on the Principal
Market, the Company shall issue a press release announcing the transaction and any other material, non-public information previously
disclosed by the Company or any Person acting on its behalf to any of the Buyers or their agents or counsel (the “Press Release”)
and the Company shall issue a Current Report on Form 8-K disclosing the material terms hereof and including this Agreement and
the Warrant as exhibits thereto within 48 hours (including any material non-public information relating thereto which has been
provided by the Company or any Person acting on its behalf to any of the Buyers or their agents or counsel) of the Agreement’s
execution by all parties hereto. The Company understands and confirms that the Buyers will rely on the foregoing representations
and covenants in effecting transactions in securities of the Company. All disclosure provided to the Buyers regarding the Company,
its business and the transactions contemplated hereby, furnished by or on behalf of the Company (including the Company’s
representations and warranties set forth in this Agreement), taken as a whole, are true and correct and do not contain any untrue
statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in the
light of the circumstances under which they were made, not misleading.

 

(i)          Acknowledgment
Regarding Buyer’s Purchase of Securities. The Company acknowledges and agrees that each Buyer is acting solely in the
capacity of arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated hereby and
thereby. The Company further represents to each Buyer that the Company’s decision to enter into the Transaction Documents
has been based solely on the independent evaluation by the Company and its representatives.

 

    	8

    	 

    

 

(j)          Material
Changes; Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial statements included
within the SEC Reports, except as specifically disclosed in a subsequent SEC Report filed prior to the date hereof: (i) there has
been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect,
including without limitation, any breach of or event of default under the Note (ii) the Company has not incurred any liabilities
(contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent
with past practice and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to GAAP
or disclosed in filings made with the SEC, (iii) the Company has not altered its method of accounting, (iv) the Company
has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made
any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity securities
to any officer, director or affiliate, except pursuant to existing Company equity incentive plans. The Company does not have pending
before the SEC any request for confidential treatment of information. Except as set forth in the Prospectus and for the issuance
of the Securities contemplated by this Agreement, no event, liability, fact, circumstance, occurrence or development has occurred
or exists or is reasonably expected to occur or exist with respect to the Company and its businesses, properties, operations, assets
or financial condition, that would be required to be disclosed by the Company under applicable securities laws.

 

(k)          Litigation.
There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company,
threatened against or affecting the Company or any of its assets before or by any court, arbitrator, governmental or administrative
agency or regulatory authority (federal, state, county, local or foreign) (collectively, an “Action”) which
(i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities
or (ii) could, if there were an unfavorable decision, reasonably be expected to result in a Material Adverse Effect. Neither
the Company, nor, to the knowledge of the Company, any director or officer thereof, is or has been the subject of any Action involving
a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not
been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the SEC involving the Company
or any current or former director or officer of the Company. The SEC has not issued any stop order or other order suspending the
effectiveness of any registration statement filed by the Company under the 1934 Act or the 1933 Act.

 

(l)          Patents
and Trademarks. The Company has, or has rights to use, all patents, patent applications, trademarks, trademark applications,
service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar
rights as described in the SEC Reports as necessary or material for use in connection with their respective businesses and which
the failure to have could reasonably be expected to have a Material Adverse Effect (collectively, the “Intellectual Property
Rights”). The Company has not received any notice of a claim or otherwise has any knowledge that the Intellectual Property
Rights violate or infringe upon the rights of any Person which have could reasonably be expected to have a Material Adverse Effect.
To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by
another Person of any of the Intellectual Property Rights. The Company has taken reasonable security measures to protect the secrecy,
confidentiality and value of all of its Intellectual Property Rights, except where failure to do so could not, individually or
in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

    	9

    	 

    

 

(m)          Maintenance
Requirements. The Common Stock is registered pursuant to Section 12(g) of the 1934 Act, and the Company has taken no action
designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under
the 1934 Act nor has the Company received any notification that the SEC is contemplating terminating such registration.

 

(n)          FDA.
As to each product or product candidate of the Company described in the SEC Reports or other product or product candidate of the
Company that is subject to the jurisdiction of the U.S. Food and Drug Administration (“FDA”) under the Federal
Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (“FDCA”) that is manufactured, packaged,
labeled, tested, distributed, sold, and/or marketed by the Company (each such product, a “Pharmaceutical Product”),
such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company
in compliance with all applicable requirements under FDCA and similar foreign or domestic laws, rules and regulations relating
to registration, investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good
laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports,
except where the failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the
Company’s knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding,
charge, complaint, or investigation) against the Company, and the Company has not received any notice, warning letter or other
communication from the FDA or any other Person, which (i) contests the premarket clearance, licensure, registration, or approval
of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion
of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws
or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a
clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility
of the Company or any of commercial or contract partners, (v) enters or proposes to enter into a consent decree of permanent
injunction with the Company or any of its commercial or contract partners, or (vi) otherwise alleges any violation of any
laws, rules or regulations by the Company or any of its commercial or contract partners, and which, either individually or in the
aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company and, to the knowledge of
the Company, its commercial or contract partners, have been and are being conducted in all material respects in accordance with
all applicable laws, rules and regulations of the FDA. The Company has not been informed by the FDA that the FDA will prohibit
the marketing, sale, license or use in the United States of any product proposed to be developed, produced or marketed by the Company
nor has the FDA expressed any concern as to approving or clearing for marketing any product being developed or proposed to be developed
by the Company.

 

4.          COVENANTS.

 

(a)          Best
Efforts. Each party shall use its best efforts timely to satisfy each of the covenants and the conditions to be satisfied by
it as provided in Sections 4, 5 and 6 of this Agreement.

 

    	10

    	 

    

 

(b)          Prospectus
Supplement. On or before the Closing, the Company shall have delivered the Prospectus Supplement with respect to the Securities
as required under and in conformity with the 1933 Act, including Rule 424(b) thereunder.

 

(c)          OTC-BB
Maintenance. The Company shall not take any action which would be reasonably expected to result in the termination of quotation
on or suspension of the Common Stock on the Principal Market.

 

(d)          Warrant
Shares. If all or any portion of a Warrant is exercised at a time when there is an effective registration statement to cover
the issuance of the Warrant Shares or if the Warrant is exercised via cashless exercise, the Warrant Shares issued pursuant to
any such exercise shall be issued free of all legends. If at any time following the date hereof a Buyer (or holder) provides a
notice of exercise with respect to a Warrant to the Company and at such time the Registration Statement (or any subsequent registration
statement registering the sale of the Warrant Shares) is not effective or is not otherwise available for the issuance of the Warrant
Shares, the Company shall immediately notify such Buyer (or holder of the Warrants) in writing that such registration statement
is not then effective and thereafter shall promptly notify such Buyer (or holder) when the registration statement is effective
again and available for the issuance of the Warrant Shares (it being understood and agreed that the foregoing shall not limit the
ability of the Company to issue, or any Purchaser to sell, any of the Warrant Shares in compliance with applicable federal and
state securities laws). If at any time following the date hereof the Registration Statement is not effective or is not otherwise
available for the issuance of the Securities or any prospectus contained therein is not available for use, the Company shall immediately
notify the holders of the Securities in writing that the Registration Statement is not then effective or a prospectus contained
therein is not available for use and thereafter shall promptly notify such holders when the Registration Statement is effective
again and available for the issuance of the Securities or such prospectus is again available for use.

 

(e)          Furnishing
of Information. Until the earlier of the time that (i) no Buyer owns Securities or (ii) the Warrants have terminated or expired,
the Company covenants to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all
reports required to be filed by the Company after the date hereof pursuant to the 1934 Act. As long as any Buyer owns Securities,
if the Company is not required to file reports pursuant to the 1934 Act, it will prepare and make publicly available in accordance
with Rule 144(c) such information as is required for the Purchasers to sell the Securities under Rule 144. The Company further
covenants that it will use commercially reasonable efforts to take such further action as any Buyer (which at such time owns any
Shares or Warrants) may reasonably request, to the extent required from time to time to enable such Person to sell such Securities
without registration under the 1933 Act, including without limitation, within the requirements of the exemption provided by under
Rule 144.

 

    	11

    	 

    

 

(f)          Limitation
on Short Sales and Hedging Transactions. Each Buyer severally and not jointly with the other Buyers, covenants that neither
it, nor any "affiliate" (as that term is defined under Rule 405 of the 1993 Act) acting on its behalf or pursuant to
any understanding with it will execute any purchases or sales, including "short sales" (as such term is defined in Section
242.200 of Regulation SHO of the 1934 Act), of any of the Company's securities during the period commencing with the execution
of this Agreement and ending at such time that the transactions contemplated by this Agreement are first publicly announced pursuant
to the Press Release. Each Buyer, severally and not jointly with the other Buyers, covenants that until such time as the transactions
contemplated by this Agreement are publicly disclosed by the Company pursuant to the Press Release, such Buyer will maintain the
confidentiality of the existence and terms of this transaction and the information included in the Transaction Documents. Notwithstanding
the foregoing, and notwithstanding anything contained in this Agreement to the contrary, the Company expressly acknowledges and
agrees that (i) no Buyer makes any representation, warranty or covenant hereby that it will not engage in effecting transactions
in any securities of the Company after the time that the transactions contemplated by this Agreement are first publicly announced
pursuant to the Press Release, (ii) no Buyer shall be restricted or prohibited from effecting any transactions in any securities
of the Company in accordance with applicable securities laws from and after the time that the transactions contemplated by this
Agreement are first publicly announced pursuant to the Press Release and (iii) no Buyer shall have any duty of confidentiality
to the Company or its Subsidiaries after the issuance of the Press Release. Notwithstanding the foregoing, in the case of a Buyer
that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Buyer's assets
and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions
of such Buyer's assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the portfolio
manager that made the investment decision to purchase the Securities covered by this Agreement.

 

5.          CONDITIONS
TO THE COMPANY’S OBLIGATION TO SELL.

 

The obligation of the
Company hereunder to issue and sell the Securities to each Buyer at the Closing is subject to the satisfaction, at or before the
Closing Date, of each of the following conditions, provided that these conditions are for the Company’s sole benefit and
may be waived by the Company at any time in its sole discretion by providing each Buyer with prior written notice thereof:

 

(i)          Such
Buyer shall have executed this Agreement and delivered the same to the Company.

 

(ii)         Such
Buyer shall have delivered to the Company the Purchase Price for the Securities being purchased by such Buyer at the Closing by
wire transfer of immediately available funds pursuant to the wire instructions provided by the Company or by check as set forth
in Section 1(d) hererinabove.

 

(iii)        The
representations and warranties of such Buyer shall be true and correct in all material respects as of the date when made and as
of the Closing Date as though made at that time (except for representations and warranties that speak as of a specific date), and
such Buyer shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions
required by this Agreement to be performed, satisfied or complied with by such Buyer at or prior to the Closing Date.

 

    	12

    	 

    

 

6.          CONDITIONS
TO EACH BUYER’S OBLIGATION TO PURCHASE.

 

The obligation of each
Buyer hereunder to purchase the Securities at the Closing is subject to the satisfaction, at or before the Closing Date, of each
of the following conditions, provided that these conditions are for each Buyer’s sole benefit and may be waived by such Buyer
at any time in its sole discretion by providing the Company with prior written notice thereof:

 

(i)          The
Company shall have executed and delivered to such Buyer each of the Transaction Documents.

 

(ii)         The
representations and warranties of the Company shall be true and correct in all material respects as of the date when made and as
of the Closing Date as though made at that time (except for representations and warranties that speak as of a specific date) and
the Company shall have performed, satisfied and complied with the covenants, agreements and conditions required by the Transaction
Documents to be performed, satisfied or complied with by the Company at or prior to the Closing Date.

 

(iii)        The
Common Stock (I) shall be quoted on the Principal Market and (II) shall not have been suspended, as of the Closing Date, by the
SEC or the Principal Market from quotation on the Principal Market nor shall suspension by the SEC or the Principal Market have
been threatened, as of the Closing Date, either in writing by the SEC or the Principal Market.

 

(iv)        The
Registration Statement shall be effective and available for the issuance and sale of the Securities hereunder and the Company shall
have delivered to such Buyer the Prospectus as required thereunder.

 

7.          TERMINATION.
In the event that the Closing shall not have occurred with respect to a Buyer on the Closing Date due to the Company’s or
such Buyer’s failure to satisfy the conditions set forth in Sections 5 and 6 above (and the nonbreaching party’s failure
to waive such unsatisfied condition(s)), the nonbreaching party shall have the option to terminate this Agreement with respect
to such breaching party at the close of business on such date without liability of any party to any other party.

 

8.          MISCELLANEOUS.

 

(a)          Governing
Law; Venue. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be
governed by the internal laws of the State of Delaware, without giving effect to any choice of law or conflict of law provision
or rule (whether of the State of Delaware or any other jurisdictions) that would cause the application of the laws of any jurisdictions
other than the State of Delaware; provided, however, in the event that any legal proceeding is brought against the DBED
or the State of Maryland in connection with such entity’s investment in the Securities hereunder, the parties to any such
dispute agree to submit to the venue of the Maryland courts for purposes of resolving any and all such disputes.

 

    	13

    	 

    

 

(b)          Counterparts.
This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to the other party. In the event that
any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature
shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same
force and effect as if such facsimile or “.pdf” signature page were an original thereof.

 

(c)          Headings.
The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this
Agreement.

 

(d)          Severability.
If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall
not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability
of any provision of this Agreement in any other jurisdiction.

 

(e)          Entire
Agreement; Amendments. This Agreement supersedes all other prior oral or written agreements between the Buyers, the Company,
their affiliates and Persons acting on their behalf with respect to the matters discussed herein, and this Agreement and the instruments
referenced herein contain the entire understanding of the parties with respect to the matters covered herein and therein and, except
as specifically set forth herein or therein, neither the Company nor any Buyer makes any representation, warranty, covenant or
undertaking with respect to such matters. No provision of this Agreement may be amended other than by an instrument in writing
signed by the Company and the holders of the Securities, or, if prior to the Closing Date, those Buyers listed on the Schedule
of Buyers. No provision hereof may be waived other than by an instrument in writing signed by the party against whom enforcement
is sought.

 

(f)          Notices.
Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must
be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent
by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending
party); or (iii) one Business Day after deposit with an overnight courier service, in each case properly addressed to the party
to receive the same. The addresses and facsimile numbers for such communications shall be:

 

If to the Company:

 

Cytomedix, Inc.

209 Perry Parkway, Suite 7

Gaithersburg, MD 20877

Tel: (240) 499-2680

Fax: (240) 499-2690

Attn: Chief Financial Officer

 

    	14

    	 

    

 

If to a Buyer, to its
address and facsimile number set forth on the Schedule of Buyers, with copies to such Buyer’s representatives as set forth
on the Schedule of Buyers, or to such other address and/or facsimile number and/or to the attention of such other Person as the
recipient party has specified by written notice given to each other party five (5) days prior to the effectiveness of such change.
Written confirmation of receipt (A) given by the recipient of such notice, consent, waiver or other communication, (B) mechanically
or electronically generated by the sender’s facsimile machine containing the time, date, recipient facsimile number and an
image of the first page of such transmission or (C) provided by an overnight courier service, shall be rebuttable evidence of personal
service, receipt by facsimile or receipt from an overnight courier service in accordance with clause (i), (ii) or (iii) above,
respectively.

 

(g)          No
Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted
successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

 

(h)          Grant
of Right. The Affiliate Buyer (as defined below) shall have the right to include the Registrable Securities (as defined below)
as part of any other registration of securities filed by the Company (other than a registration statement (i) filed in connection
with any employee stock option or other benefit plan pursuant to Form S-8 or any equivalent form, (ii) for an exchange offer or
offering of securities solely to the Company’s existing shareholders, (iii) for a dividend reinvestment plan, or (iv) filed
by the Company to register certain securities of the Company issuable to the Lincoln Park Capital Fund, LLC (“LPC”)
pursuant to the terms of those certain Purchase Agreement and Registration Rights Agreement, each by and between the Company and
LPC, each dated as of February 18, 2013, in each case on the same terms and conditions as any similar securities of the Company
being registered (other than duration of the registration rights, which shall be governed solely by this Section8(h) and to permit
the sale or other disposition of such Registrable Securities in accordance with the intended method(s) of distribution thereof
only to the extent such Registrable Securities have not been previously registered for resale by the Affiliate Buyer or are otherwise
able to be resold without restriction; provided, however, that, in the case of an underwritten offering, if, in the written opinion
of the Company’s managing underwriter or underwriters, if any, for such offering, the inclusion of the Registrable Securities,
when added to the securities being registered by the Company or the selling stockholder(s), will exceed the maximum amount of the
Company’s securities which can be marketed without materially and adversely affecting the entire offering, then the Company
will still be required to include the Registrable Securities, but may require the Affiliate Buyer to agree, in writing, to delay
the sale of all or any portion of the Registrable Securities for a period of ninety (90) days from the effective date of the underwritten
offering, provided, further, that if the sale of any Registrable Securities is so delayed, then the number of securities to be
sold by all selling stockholders in such underwritten offering during such ninety (90) day period shall be apportioned pro rata
among all such selling stockholders, including all holders of the Registrable Securities, according to the total amount of securities
of the Company owned by said selling stockholders, including all holders of the Registrable Securities. Notwithstanding the foregoing,
to the extent that the Registrable Securities have not been registered by the Company as contemplated above at the time the Company
is required to file a registration statement in connection with the final Milestone Event (the “Milestone Event Registration
Statement”) as set forth in Section 9.7 of that certain Exchange And Purchase Agreement dated February 8, 2012, by and among
the Company, Aldagen, Inc., a Delaware corporation, and Aldagen Holdings, LLC, a North Carolina limited liability company (the
“Agreement”), the Affiliate Buyer shall have the right to include such Registrable Securities in the Milestone Event
Registration Statement. Capitalized terms used in this paragraph and not defined herein shall have the meanings given such terms
in Section 9.7 of the Agreement.

 

    	15

    	 

    

 

The Company shall
bear all fees and expenses attendant to registering the Registrable Securities contemplated hereunder, but the Affiliate Buyer
shall pay any and all underwriting commissions. In the event of such a proposed registration, the Company shall furnish the then
Affiliate Buyer of outstanding Registrable Securities with not less than ten (10) days written notice prior to the proposed date
of filing of such initial registration statement. Such notice to the Affiliate Buyer shall continue to be given for each initial
registration statement filed by the Company until such time as all of the Registrable Securities have been sold by the Affiliate
Buyer. The holders of the Registrable Securities shall exercise the "piggy-back" rights provided for herein by giving
written notice, within five (5) days of the receipt of the Company's notice of its intention to file a registration statement.
As used in this Section, the term “Affiliate Buyer” means a Buyer of the Securities who is deemed an “affiliate”
of the Company as such term is defined under the 1933 Act and rules and regulations promulgated thereunder.

 

As used in this
Section, the term “Registrable Securities” means (i) all of the Securities and the Warrant Shares which may from time
to time be issued or issuable to the Buyer under this Agreement (without regard to any limitation or restriction on purchases),
and (ii) any shares of capital stock issued or issuable with respect to the Securities and the Warrant Shares as a result of any
stock split, stock dividend, recapitalization, exchange or similar event or otherwise.

 

(i)          Independent
Nature of Buyers’ Obligations and Rights. The obligations of each Buyer under any Transaction Document are several and
not joint with the obligations of any other Buyer, and no Buyer shall be responsible in any way for the performance of the obligations
of any other Buyer under any Transaction Document. Nothing contained herein or in any other Transaction Document, and no action
taken by any Buyer pursuant hereto or thereto, shall be deemed to constitute the Buyers as a partnership, an association, a joint
venture or any other kind of entity, or create a presumption that the Buyers are in any way acting in concert or as a group with
respect to such obligations or the transactions contemplated by the Transaction Documents. Each Buyer confirms that it has independently
participated in the negotiation of the transaction contemplated hereby with the advice of its own counsel and advisors. Each Buyer
shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this
Agreement or out of any other Transaction Documents, and it shall not be necessary for any other Buyer to be joined as an additional
party in any proceeding for such purpose.

 

[Signature Page Follows]

 

    	16

    	 

    

 

IN WITNESS WHEREOF,
each Buyer and the Company have caused their respective signature page to the Securities Purchase Agreement to be duly executed
as of the date first written above.

 

	COMPANY:
	 
	CYTOMEDIX, INC.
	 	 	 

	By:	/s/ Martin P. Rosendale	 
	 	 	 
	Name:	Martin P. Rosendale	 
	Title:	Chief Executive Officer	 

 

    	17

    	 

    

 

IN WITNESS WHEREOF,
each Buyer and the Company have caused their respective signature page to the Securities Purchase Agreement to be duly executed
as of the date first written above.

 

BUYER:

 

	By:	/s/ Jonathan Cope	 
	 	 	 
	 	Name: Jonathan Cope	 
	 	Title: President	 

 

    	18

    	 

    

 

SCHEDULE OF BUYERS

 

	
        (1)

        Name of Buyer

        Purchasing

        The Securities
	
 

	
        (2)

        Address, Contact

        Person, Telephone

        and Facsimile Number

        of the Buyer
	
 

	
        (3)

        Number of

        Common Stock

        Purchased

        Hereunder
	
 

	
        (4)

        Number of

        Warrants

        Purchased

        Hereunder
	
 

	
        (5)

        Aggregate

        Purchase Price

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 

 

    	19

    	 

    

 

Exhibit A

 

Form of Warrant

 

    	20

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}]]